Suvorexant
4 NDCs across 1 manufacturer|0 Generic,4 Brand
Suvorexant is used to treat sleep initiation and maintenance disorders, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Aug 13, 2014. In 2024, Medicare Part D spent $150 million on Suvorexant across 315,000 claims for 77,000 beneficiaries.
Suvorexant is available as 4 NDCs from 1 manufacturer (0 generic, 4 brand), with NADAC prices from $15.20 to $15.21 per EA — a 0% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
4
0G / 4B
Manufacturers
1
competing in market
Price Spread
$15.20 – $15.21
per EA
7d Activity
avg +0.0% WoW · of 4 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
1 manufacturer producing SUVOREXANT
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
BELSOMRA 5 MG TABLET | $15.2138 per EA | +0.07% |
BELSOMRA 10 MG TABLET | $15.2097 per EA | +0.01% |
BELSOMRA 20 MG TABLET | $15.2070 per EA | +0.01% |
BELSOMRA 15 MG TABLET | $15.1988 per EA | +0.04% |
Frequently Asked Questions
What is Suvorexant used to treat?
Suvorexant is used to treat sleep initiation and maintenance disorders, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Suvorexant?
In 2024, Medicare Part D spent $150 million on Suvorexant across 315,000 claims for 77,000 beneficiaries.
How many Suvorexant products are on the market?
The Suvorexant drug market contains 4 NDCs from 1 manufacturer — 0 generic and 4 brand products.
What is the price range for Suvorexant?
NADAC reference prices for Suvorexant range from $15.1988 to $15.2138 per EA — a 0% difference between cheapest and most expensive.
Which manufacturers make Suvorexant?
1 manufacturer lists Suvorexant in NADAC. Ranked by number of NDCs, the largest are Merck Sharp & Dohme LLC (4).
How has the price of Suvorexant changed recently?
Over the past 7 days, 4 Suvorexant NDCs rose and 0 fell, with a market-wide average change of +0.0%.